Opinion

Video

Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

Author(s):

Catherine C. Coombs, MDMatthew S. Davids, MD, MMSc

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

  1. Briefly comment on recent real world data regarding switching and sequencing to next line of therapy in patients with CLL. (Pinilla-Ibarz, et al. EHA 2024. Abstract P697)
  2. How do you interpret these data and how may they influence your overall treatment approach?
Related Videos
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Alexey Danilov, MD, PhD
1 KOL is featured in this series.
John Seymour, MBBS, FRACP, PhD
3 KOLs are featured in this series.
3 KOLs are featured in this series.
A panel of 5 experts on CLL
Related Content
Javier Pinilla-Ibarz, MD, PhD, senior member, head, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center
September 9th 2024

Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Alessandra Tedeschi, MD
August 30th 2024

Early Data Show High Responses With Zanubrutinib Plus Venetoclax in Treatment-Naive Del17p/TP53+ CLL/SLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

US FDA
August 26th 2024

FDA Grants Fast Track Designation to BGB-16673 in Previously Treated CLL/SLL

Matthew S. Davids, MD, MMSc
August 16th 2024

Acalabrutinib With/Without Obinutuzumab Is Effective in Higher-Risk Chronic Lymphocytic Leukemia